Epoprostenol (EPO) improves hemodynamics and survival in patients with advanced pulmonary arterial hypertension (PAH) by vessel dilatation and inhibiting platelet aggregation. 1 -3 However, it requires continuous infusion and may lead to catheter-related complications (CRCs) (infection, thromboembolism, or bleeding). In patients with indwelling central venous catheters, the incidence of catheter infection varies from 0.3 to 9.1 infections per 1,000 patient-days. 4 -6 The incidence of local infection in EPO users is 0.49 per patient-year and that of catheter-related bloodstream infection is 0.09 per patient-year. 3 We sought to investigate incidence and determinants of CRC in patients with advanced PAH who required long-term central venous access for EPO infusion. Records of 65 consecutive patients who were given an EPO infusion were reviewed retrospectively from 1998 to 2008. All patients underwent surgical implantation of a cuffed catheter (Hickman; CR Bard, Inc) for EPO infusion.
To the Editor:
Epoprostenol (EPO) improves hemodynamics and survival in patients with advanced pulmonary arterial hypertension (PAH) by vessel dilatation and inhibiting platelet aggregation. 1 -3 However, it requires continuous infusion and may lead to catheter-related complications (CRCs) (infection, thromboembolism, or bleeding). In patients with indwelling central venous catheters, the incidence of catheter infection varies from 0.3 to 9.1 infections per 1,000 patient-days. 4 -6 The incidence of local infection in EPO users is 0.49 per patient-year and that of catheter-related bloodstream infection is 0.09 per patient-year. 3 We sought to investigate incidence and determinants of CRC in patients with advanced PAH who required long-term central venous access for EPO infusion. Records of 65 consecutive patients who were given an EPO infusion were reviewed retrospectively from 1998 to 2008. All patients underwent surgical implantation of a cuffed catheter (Hickman; CR Bard, Inc) for EPO infusion.
During a median follow-up period of 6.4 years (interquartile range, 3.3-8.8), 27 patients (41.5%) developed catheter-related tunnel infection. Only fi ve patients (7.6%) developed central venous catheter-related bloodstream infection (0.03 per 1,000 catheterdays), and there were no thromboembolic or bleeding complications. The univariate logistic regression analysis showed that severity of disease, concurrent receipt of steroid therapy, and presence or absence of diabetes were not related to development of catheter-related infection (CRI), whereas patients who received a catheter on the left side of the chest (longer indwelling catheter) (OR, 2.72; 95% CI, 1.16-8.28) or wounds that were covered with dressings (OR, 2.85; 95% CI, 1.16-9.08) had a high tendency to develop CRI ( Table 1 ) .
The lower incidence of CRI in patients with advanced PAH than that in patients without PAH may occur because many patients with PAH are often very motivated to learn about their disease, participate in their treatment, and take extra precautions to improve their quality of life and survival. In addition, other reasons may include the fact that few patients with PAH have received chemotherapy leading to neutropenia and the antiplatelet effect of EPO itself.
Guidelines by the Healthcare Infection Control Practices Advisory Committee of the Centers for Disease Control and Prevention listed as unresolved the issue that no recommendation can be made regarding the necessity for any dressing on well-healed exit sites of long-term cuffed and tunneled central venous catheters. 7 Continuous EPO infusion is associated with some limi tations, including infection, but the benefi ts are becoming increasingly relevant in the ambulatory setting. Prospective investigation is warranted. 
High Correlation Between Salivary Cortisol and Free Serum Cortisol Measurements Does Not Mean Good Agreement
To the Editor:
I read with great interest the study by Estrada-Y-Martin and Orlander 1 published recently in CHEST (November 2011). According to the study, salivary cortisol can replace free serum cortisol in patients with septic shock because of a good correlation between these variables. However, the correlation coeffi cient is of no practical use in the statistical analysis of comparison data. 2 Indeed, the high correlation between salivary cortisol and free cortisol measurements does not mean that the two methods agree. 3 The correlation coeffi cient in this case depends on both the variation between individuals and the variation within individuals (measurement error). Therefore, the correlation coefficient will partly depend on the choice of patients; if the variation between patients is high compared with the measurement error, the correlation will be high, whereas if the variation between patients is low, the correlation will be low no matter how good the agreement between the two methods. 4 Consequently, when measurements are taken by two methods on a group of patients, the variation between patients will introduce a strong correlation between the two sets of measurements. This correlation is, of course, irrelevant for the method comparison. Thus, it is quite wrong to infer from high correlation that the salivary cortisol and free serum cortisol measurements may be used interchangeably.
A more appropriate approach would be to plot the difference between salivary cortisol and free serum cortisol measurements against their mean and to calculate the bias (the mean difference between the two measurements) and the 95% limits of agreement for the prediction interval for the differences as previously described by Bland and Altman. 3 If this interval is sufficiently tight around 0 from a clinical point of view, salivary cortisol measurement can replace free serum cortisol measurement.
Inappropriate use of a regression analysis and correlation coeffi cient to the analysis of measurement method comparison data remains common in medicine, despite being well recognized. We should not forget that the correlation coeffi cient is a measure of association; it is not a measure of agreement.
Jihad Mallat, MD
Lens, France 
Response
I welcome the comments of Dr Mallat regarding our article. 1 Although I agree with the comments, the purpose of our study was not only to correlate free serum cortisol and salivary cortisol but also to create a regression equation that would allow for the prediction of free serum cortisol. The determination of total serum cortisol is a poor surrogate of free serum cortisol because it includes bound and unbound hormone and only free serum cortisol is functionally active. Salivary cortisol is a better surrogate as demonstrated by our study. 1 Ideally, we would like to know the free serum cortisol concentration in patients with septic shock to decide whether replacement is necessary; however, the test is technically Figure 1 . Bland-Altman plot between salivary cortisol and free serum cortisol (38 patients). Limits of agreement, 2 3.045-4.090; mean difference, 0.523; 95% CI, 2 0.064-1.109; range, 0.180-11.040; Pitman test r , 0.702; P 5 .001.
